News und Analysen

The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.

And

Shares of Omeros (NASDAQ: OMER) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.

It was a deal with the Danish

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

An SEC filing dated

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of

Graphene Investments SAS fully exited its position in Centene Corporation (NYSE:CNC) during the third quarter, selling approximately 55,600 shares in a transaction estimated at ~$3.02 million as of

On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (NASDAQ:INCY), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this

One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing

Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to

A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more

On October 10, 2025, Sarasin & Partners LLP disclosed a significant reduction in its UnitedHealth Group (NYSE:UNH) stake, selling 465,744 shares in an estimated $140.86 million trade.

Sarasin &amp

Viking Therapeutics (NASDAQ: VKTX) soared to the forefront almost two years ago when it announced data on an investigational drug to serve an area of high need: weight loss. The biotech's candidate

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining

The 6.7% dividend yield on offer from Pfizer (NYSE: PFE) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable. But

Nektar Therapeutics (NASDAQ: NKTR) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January. Yet, some analysts

If you are looking for high-yield stocks in a stock market that is hovering near all-time highs, a good place to start your search is with reliable dividend payers.

Dividend Champions fit the bill

UnitedHealth (NYSE: UNH) shares are up significantly since I upgraded the stock to a buy rating.

*Stock prices used were the afternoon prices of Oct. 6, 2025. The video was published on Oct. 8

There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer

The leading pipeline drug being developed by Cidara Therapeutics (NASDAQ: CDTX) got a real boost from a regulator on Thursday, and the biotech's share price moved accordingly. Cidara's stock closed

Shares in Viking Therapeutics (NASDAQ: VKTX) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.

According to a filing

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices

Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications